ImageneBio, Inc. Reports Board and Executive Compensation Changes
Ticker: IMA · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1835579
| Field | Detail |
|---|---|
| Company | Imagenebio, INC. (IMA) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
TL;DR
ImageneBio shuffled its board and updated exec pay. Watch for strategy shifts.
AI Summary
ImageneBio, Inc. announced on December 12, 2025, a change in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of a director and the election of a new director, along with updates to the compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes, while common, can introduce uncertainty regarding future strategy and leadership stability.
Key Numbers
- 001-40287 — SEC File Number (Identifies the company's filing history with the SEC.)
- 81-1697316 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- ImageneBio, Inc. (company) — Registrant
- December 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices location
- Ikena Oncology, Inc. (company) — Former company name
FAQ
Who departed from the board of directors?
The filing indicates the departure of a director, but does not name the individual in the provided text.
Who was elected to the board of directors?
The filing states a new director was elected, but does not provide the name in the provided text.
What is the exact date of the reported event?
The earliest event reported is dated December 12, 2025.
What is ImageneBio, Inc.'s principal executive office address?
The principal executive offices are located at 12526 High Bluff Drive, Suite 345, San Diego, California, 92130.
What was ImageneBio, Inc.'s former company name?
The company was formerly known as Ikena Oncology, Inc.
Filing Stats: 427 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2025-12-18 16:05:08
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IMA The Nasdaq Capital Ma
Filing Documents
- d945385d8k.htm (8-K) — 23KB
- 0001193125-25-324798.txt ( ) — 137KB
- ima-20251212.xsd (EX-101.SCH) — 3KB
- ima-20251212_lab.xml (EX-101.LAB) — 18KB
- ima-20251212_pre.xml (EX-101.PRE) — 11KB
- d945385d8k_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025 IMAGENEBIO, INC. (Exact name of registrant as specified in its charter) Delaware 001-40287 81-1697316 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 12526 High Bluff Drive , Suite 345 San Diego , California 92130 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (858) 345-6265 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value IMA The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 12, 2025, Yufang Lu, M.D., Ph.D., our Chief Medical Officer, provided notice of her resignation, effective December 31, 2025. Dr. Lu's resignation was not due to any disagreement on any matter relating to our operations, policies or practices. We are conducting a search for Dr. Lu's replacement. Dr. Lu is expected to provide transition advisory services following her resignation date. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMAGENEBIO, INC. Date: December 18, 2025 By: /s/ Kristin Yarema Kristin Yarema, Ph.D. Chief Executive Officer